Science News coverage of

ESC Congress 2019
Aug. 31 – Sept. 4, 2019 | Paris, France

This is where you'll find data summaries, results, and insightful interviews on the most important Hot Line trials from ESC19 in Paris.

Hot Lines 1 & 2 - Sunday, Sept. 1


Ivor Benjamin, MD, past president of the American Heart Association and Bob Harrington, MD, president of the American Heart Association discuss the results of THEMIS, THEMIS PCI, and DAPA HF, presented today at the European Society of Cardiology Congress 2019.

COMPLETE study results

Shamir Mehta, MD, principal investigator of the COMPLETE trial provides an overview of the results he presented during ESC 2019. See the published study, a data summary, and more.

DAPA HF study results

John McMurray, MD, principal investigator of the DAPA-HF trial summarizes the results and their implications for HFrEF patients, which he presented during ESC 2019. See a detailed summary of the trial.

ISAR-REACT 5 study results

Stefanie Schüpke, MD, principal investigator for ISAR-REACT 5, summarizes the surprising results of this head-to-head comparison of ticagrelor versus prasugrel. Read the published paper, and see a detailed data summary of the trial.

THEMIS: Main Results of the Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study
Deepak Bhatt | Newton, MA
THEMIS-PCI: Ticagrelor in Patients with Diabetes and Stable Coronary Artery Disease with a History of Prior Percutaneous Coronary Intervention
Philippe Gabriel Steg | Paris, France

PARAGON HF: Angiotensin Receptor Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Scott Solomon | Boston, MA

COMPLETE: Revascularization with Multivessel Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction
Shamir R Mehta | Hamilton, Canada

DAPA HF - The Dapagliflozin And Prevention Of Adverse-outcomes In Heart Failure Trial
John McMurray | Glasgow, UK

NZOTACS - The New Zealand Oxygen Therapy in Acute Coronary Syndromes trial
Ralph Stewart | Auckland, New Zealand

CONDI-2/ERIC-PPCI - Effect of remote ischemic conditioning on clinical outcomes in patients with ST- segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
Bernard Gersh | Rochester, Minn.

ISAR-REACT 5 - Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
Stefanie Schuepke | Munich, Germany

HiSTORIC - High-Sensitivity cardiac Troponin On presentation to Rule out myocardial InfarCtion: A stepped-wedge cluster randomised controlled trial
Nicholas Mills | Edinburgh, UK

Hot Lines 3 & 4 - Monday, Sept. 2

HOPE 4 study results

J.D. Schwalm, MD, lead author of the HOPE 4 study, provides an overview of the results of the HOPE 4 study and what they suggest for improving the management of hypertension worldwide. See HOPE 4 details.


Ivor Benjamin, MD, Bob Harrington, MD, and Mitch Elkind, MD, MS, MPhil discuss the results of AFIRE, HOPE 4, and COMPLETE, and which were presented during ESC 2019.

GALACTIC study results

Christian Müller, MD, principal investigator for the GALACTIC study, summarizes the findings, which he presented this week. See results and a detailed look at GALACTIC data in our at-a-glance summary slide.

MITRA FR 2 year results

Jean-François Obadia, MD, principal investigator of the MITRA FR study, provides an overview of the 2-year follow-up results. See MITRA FR's data summary slide and more.

AFIRE - Rivaroxaban monotherapy versus combination therapy in patients with atrial fibrillation and stable coronary artery disease
Satoshi Yasuda | Suita, Japan

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial
Christian Eugen Mueller | Basel, Switzerland

HOPE 4 – Impact on cardiovascular risk of a community-based multi-faceted intervention in individuals with hypertension in 2 middle income countries: The Heart Outcomes Prevention and Evaluation 4 study
JD Schwalm | Hamilton, Canada

BB-meta-HF - Beta-blockers are effective in high-risk heart failure patients with reduced ejection fraction and moderately-severe renal dysfunction
Dipak Kotecha | Birmingham, UK

SYNTAXES - Ten-Year Survival after Coronary Artery Bypass Grafting versus Percutaneous Coronary Intervention: The SYNTAX Extended Survival study
Daniel Johannes Franciscus Maria Thuijs | Rotterdam, The Netherlands

MITRA-FR - 2 years follow-Up of the MITRA-FR study a randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation
Jean-Francois Obadia | Lyon-Bron Cedex, France

Hot Lines 5 & 6 - Tuesday, Sept. 3

ESC 2019: PARAGON HF, Salt Substitution, POPular Genetics, DAPA-HF

Ivor Benjamin, MD, Bob Harrington, MD, and Mitch Elkind, MD, MS, MPhil review the top science presented for ESC 2019, including PARAGON-HF, Salt Substitution, POPular Genetics, and DAPA-HF.

Attendees enjoyed the weather during a break at ESC19.

Enjoying the days in Paris

Attendees managed to spend some time outside the convention space during a break in presentations as the end of summer draws near.

PURE - Contrasting patterns of cardiovascular disease, cancers and related mortality between high- versus low-middle income countries in 21 countries
Darryl Leong | Hamilton, Canada

  • RESULTS: CVD remains the main cause of death globally, but cancer has overtaken it in some high-income countries (HIC) and upper-middle-income countries (MIC). Overall mortality was highest in low-income countries (LIC), intermediate in MIC, and lowest in HIC.
  • Original PURE study in The Lancet (opens in new window)

PURE - Impact of modifiable risk factors on cardiovascular disease and mortality
Salim YUSUF | Hamilton, Canada

  • RESULTS: The high mortality in poorer countries might be primarily related to poorer access to health care. Substantial further reductions in CVD are possible with wider adoption of proven prevention strategies and treatments in all countries.
  • Original PURE study in The Lancet (opens in new window)

RAPID-TnT - A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T
Derek Chew | Adelaide, Australia

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients.
Andreas Goette | Paderborn, Germany

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with ST-segment elevation myocardial infarction undergoing primary PCI: a randomized, open-label, multicenter trial
Danny Claassens | The Netherlands

DAPA - Long-term outcome of the Defibrillator After Primary Angioplasty Trial - Implantable Defibrillator Early After Primary Percutaneous Intervention for ST-Elevation Myocardial infarction
Danielle Marianne Haanschoten | Zwolle, The Netherlands